Drugs by condition
Drugs approved for covid-19
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
11
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
5
New molecular entities and new biologics
In development
19
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for covid-19.
All approved drugs for covid-19, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Interleukin-6 Receptor Antagonist (7)
- Actemra Tocilizumab · Genentech · 2010
- Avtozma Tocilizumab-Anoh · Celltrion INC · 2026
- Tyenne Tocilizumab-Aazg · Fresenius Kabi USA · 2025
- Avtozma Tocilizumab-Anoh · Celltrion INC · 2025
- Tyenne Tocilizumab-Aazg · Fresenius Kabi USA · 2024
- Tofidence Tocilizumab-Bavi · Biogen Ma · 2023
- Actemra Tocilizumab · Genentech · 2013
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor (1)
- Veklury Remdesivir · Gilead Sciences INC · 2020
Janus Kinase Inhibitor (1)
- Olumiant Baricitinib · Eli Lilly and CO · 2018
Class not listed in FDA's data (2)
- Xocova Ensitrelvir · Shionogi · 2026
- Paxlovid (Copackaged) Nirmatrelvir, Ritonavir · Pfizer · 2023
Drugs in development for covid-19
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- ibuzatrelvirPF-07817883Phase 32 trials
Pfizer · COVID-19 SARS-CoV-2 Infection, COVID-19 Infection
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
- RVX000222apabetalone, RVX-208Phase 32 trials
Resverlogix Corp · Post-Acute COVID-19 Syndrome, Kidney Failure, Chronic
- VYD2311Phase 32 trials
Invivyd, Inc. · Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine
- DAS181Phase 31 trial
Ansun Biopharma, Inc. · Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised
- MolnupiravirMK-4482, LAGEVRIOPhase 31 trial
Merck & Co. · Coronavirus Disease (COVID-19)
- NVXC19EU licensed, standalonePhase 31 trial
Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization
- SCTA01Phase 31 trial
Sinocelltech Ltd. · COVID-19, SARS-CoV-2
- VYD222pemivibartPhase 31 trial
Invivyd, Inc. · COVID-19, SARS-CoV-2
- VYD2311-MDPhase 31 trial
Invivyd, Inc. · COVID-19
- VYD2311-SDPhase 31 trial
Invivyd, Inc. · COVID-19
- RimonabantPhase 24 trials
Sinfatin S.L · Chronic Stroke, Subacute Stroke, Post-COVID-19 Syndrome
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
- COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials
GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia
- CVXGACVXGA50, PIV5-SARS CoV-2Phase 22 trials
CyanVac LLC · COVID-19
- rC19Novavax's adjuvanted recombinant COVID-19Phase 22 trials
Sanofi · COVID-19 Immunization, Influenza Immunization
- AV-001Phase 21 trial
Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia
- GC4006APhase 21 trial
GC Biopharma Corp · Covid-19 Prevention
More on covid-19: recruiting trials · published research
Related in infectious disease and vaccines: HIV · Hepatitis B · Hepatitis C · Influenza · RSV · Urinary tract infection · Pneumonia · Skin infections · C. difficile infection · Fungal infections
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.